🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

A 🧵 on our recent study on surveillance for IR-NMIBC European Urology Oncology authors.elsevier.com/c/1l7pU_wtP00L… There is limited evidence on follow-up for IR-NMIBC. We used data from >2000 primary Ta–T1 NMIBC to stratify IR-NMIBC by recurrence risk and propose a risk-adapted follow-up approach.

ESGURS-ESAU25 will be hosted in Turin this year! We spoke to local organisers Marco Falcone and Paolo Gontero about how their department is preparing and some highlights from the scientific programme. Abstract submission is open until 10 July! ow.ly/nkkr50Wbnzv

Histopathologic features and transcriptomic signatures do not solve the issue of magnetic resonance imaging-invisible #ProstateCancers: a matched-pair analysis. #ProstateCancer invisibility on mpMRI ≠ indolence! A matched-pair study found no histopathologic or transcriptomic

In the latest video in our partnership with Dr. Glaucomflecken, the BALANCE trial comparing 7 days of antibiotic treatment with 14 days of treatment in patients with bloodstream infection is explained. Access the article for free: nej.md/DrG19

New data on hydro TMT in MIBC 🚨guess that’s why it’s not ideal 👎 📊 74% of patients with pre-existing hydronephrosis still had it post-TMT 💧 21% of patients WITHOUT hydronephrosis developed it after TMT 🧵 52% of new cases needed PCNT drainage…. rdcu.be/ethqd

🧠 Words of Wisdom in Eur Urol by Bjerklund Johansen et al: PREVENT RCT: TPBx = 0% infection, TRBx = 1.6%. Norway made the switch years ago—zero infections in 36,000+ men. RCTs matter, but sometimes common sense wins. Check this out: europeanurology.com/article/S0302-… #UroTwitter #TPBx

🔵 NEW #WoW in European Urology by Daniele Raggi Does extended lymphadenectomy (eLND) improve outcomes in MIBC? 📉 No DFS or OS benefit vs standard LND ⚠️ More severe AEs & perioperative deaths 🚫 Time to shift focus: better systemic therapy, not bigger surgery. 🧠

Medische raden negen Antwerpse ziekenhuizen: “Dreigende ontwrichting” (open brief) despecialist.eu/nl/nieuws/bero…

Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A Collaborative Systematic Review and Meta-analysis of Aggregate Data sciencedirect.com/science/articl… This systematic review and meta-analysis by the DADSPORT Collaboration

New study on Valrubicin + Docetaxel as salvage for BCG unresponsive/exposed NMIBC Eur Urol Focus Vignesh Packiam, MD 🚨 1 in 3 patients progression within 5 years. ⚠️ prostatic involvement = 2x risk of progression (p=0.02) 💢 53% adverse event rate 👎 41% recurrence-free at 3 yrs

Active Surveillance for Screen-detected Low- and Intermediate-risk Prostate Cancer: Extended Follow-up up to 25 Years in the GÖTEBORG-1 Trial sciencedirect.com/science/articl… This long-term follow-up study from the GÖTEBORG-1 screening trial evaluated outcomes in 488 men with

Ik begrijp niet goed waarom sommigen jaloers zijn op de lonen van artsen. Er is toch niets dat hen verhindert zelf arts te worden?

Investigating PARP expression as a biomarker for targeted therapy in #ProstateCancer. Emmanuel Antonarakis Masonic Cancer Center, University of Minnesota sits down with Neeraj Agarwal Huntsman Cancer Institute to unpack how PARP1 expression could redefine PARP inhibitor use in prostate cancer. In BRCA2+ patients, high PARP1 = 100%

Gem/cis/durvalumab is approved in the EU for muscle invasive bladder cancer (NIAGARA study). It’s the only immune therapy study in the adjuvant or neoadjuvant setting with significant OS. ⬆️ pCR and EFS support this appr OncoAlert Annals of Oncology astrazeneca.com/media-centre/p…

🩸💥 Many have asked: “Where did the EAU #thromboprophylaxis guideline go?” Don’t worry. Check out cluevte.org 🚀 ✅ Not just #urology, also #gynecology & abd #surgery ✅ Procedure-specific VTE & bleeding risks ✅ Free interactive tool + static infographics #EBM

Dat artsen worden neergezet als een bende graaiers, is een regelrechte schande. Alsof enkel ambtenaren met een vast loon en vaste werkuren eerlijke mensen zijn.

Can metformin boost survival in metastatic hormone-sensitive prostate cancer? 🔑 : A win for metabolic health, but not a game-changer (yet). ❌ No significant OS benefit (HR 0.91, p=0.15) ✅ Reduced ADT-related metabolic side effects 💊 Safe & well-tolerated (mostly GI issues)

Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol sciencedirect.com/science/articl… In the STAMPEDE phase 3 trial, researchers evaluated whether adding metformin to standard of care

Important work! Congrats to the group Khurshid Ghani . In absence of any contraindications, all patients get it. From 👶 to 👴. Cheap, well tolerated, .... Ask yourself: why not? (Apart from off-label use 😅). Hurray for Alpha blockers 🥳 (nuance: Careful of low BP in some)

Breaking News from ph3 Embark trial👉Enzalutamide+ADT improve overall survival (OS) vs. ADT alone in Non-Metastatic HSPC #Prostatecancer Congrats to Stephen Freedland, MD neal shore & team! Earlier enza works better! Link👉 rb.gy/iyc3f2 OncoAlert UroToday.com Prostate Cancer Foundation